The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Radiogroup Participações S.A.
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advised Radiogroup, a regional leader in cancer treatment through radiotherapy, on its sale of a majority stake to Grupo Oncoclínicas
![Saudi Arabia Saudi Arabia Flag](https://www.greenhill.com/sites/default/files/saudiarabia.gif)
Equity stake in Bupa Arabia
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
![UK/Ireland U.K., Ireland flags](https://www.greenhill.com/sites/default/files/uk-ireland_35558.gif)
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
BioD, LLC
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to an authorized generic version of Adderall XR
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 37 approved and 5 pipeline generic products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Aegerion Pharmaceuticals
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Total Care Medicaid Plan
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Boehringer Ingelheim
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Allied Healthcare
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Aesynt, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems
![Ireland Ireland flag](https://www.greenhill.com/sites/default/files/ireland.gif)
Allergan Generics
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Altegra Health, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Aralez Pharmaceuticals Inc.
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Portfolio of GlaxoSmithKline plc consumer and OTC brands
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
MannKind Corporation
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
![USA/Germany U.S.A., Germany flags](https://www.greenhill.com/sites/default/files/usa_germany.gif)
Siemens Health Services
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Clinuvel Pharmaceuticals Limited
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases